307
Participants
Start Date
February 6, 2024
Primary Completion Date
July 29, 2025
Study Completion Date
January 30, 2026
survodutide
once weekly subcutaneous injection
Placebo matching BI 456906
Once weekly subcutaneous injection
Tianjin Medical University General Hospital, Tianjin
Beijing Chao-Yang Hospital, Beijing
Peking University People's Hospital, Beijing
Beijing Pinggu Hospital, Beijing
Panjin Liao Oil Gem Flower Hospital, Panjin
The First Hospital of Jilin University, Changchun
The Second Hospital of Jilin University, Changchun
Siping Central People's Hospital, Siping
Forth Clinical Hospital of Harbin Medical University, Harbin
Shanghai Fifth People's Hospital affiliated to Fudan University, Shanghai
The Second Affiliated Hospital of Nanjing Medical University, Nanjing
Changzhou Second People's Hospital, Changzhou
Affiliated Hospital of Nantong University, Nantong
The People's Hospital Of Xuancheng City, Xuancheng
Center Hospital of Jinan, Jinan
Tianjin Medical University Chu Hisen-I Memorial Hospital, Tianjin
Huzhou Central Hospital, Huzhou
The First Affiliated Hospital of Ningbo University, Ningbo
Lishui Municipal Central Hospital, Lishui
Second Affiliated Hospital Chongqing Medical University, Chongqing
Yueyang People's Hospital, Yueyang
Wuhan Union Hospital, Wuhan
Yichang NO.1 People's Hospital, Yichang
The First Affiliated Hospital of Henan University of Science and Technology, Luoyang
NanFang Hosptial, Guangzhou
People's Hospital of Sichuan Province, Chengdu
The First Affiliated Hospital of Xi'an Medical University, Xi'an
Jincheng General Hospital, Jincheng
Lead Sponsor
Boehringer Ingelheim
INDUSTRY